BioCryst Pharmaceuticals, Inc. (BCRX) has made great progress in advancing its pipeline. That's because it is currently evaluating the use of oral D Factor inhibitor, known as BCX10013, for the ...
In a recent study published in the Science Bulletin, researchers comprehensively examined the composition and phenotypic features of myeloid cells in human failing hearts at a single-cell level, ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果